ERBB2 and breast cancer: Therefore, we used the stage IV breast cancer with HER-2-negative at the initial diagnosis from the Surveillance, Epidemiology and End Results (SEER) database to analyze the clinicopathological difference between sPR-positive phenotype and other HoR phenotypes.